Johnson & Johnson is assuming full responsibility for the manufacturing of a drug substance for its Covid-19 vaccine at Emergent BioSolutions Inc.’s Bayview facility, the company said in a statement.

It will add dedicated leaders for operations and quality, and “significantly” increase the number of manufacturing, quality and technical operations personnel at the site, according to the statement.

• Choosing the best demat account in 2025
• People’s Bank of China Stops Bond Buying
• Nifty, Sensex Suffer Biggest Weekly Loss in a Month Due to Persistent FII Selling
• Canada-Based Startup Launches North
• Economy of India Set to Grow 6.6% in 2025

The company will work closely with the Food and Drug Administration for the emergency use authorization of the specific facility, adding that all its doses so far have met regulatory quality standards. The company said it expects to deliver almost 100 million doses of the Covid-19 vaccine to the US government by the end of May.